Healthcare ranking
Top 25 neuromuscular disease clinical trial sponsors 2026
argenx started the most neuromuscular disease clinical trials as lead sponsor between November 2023 and October 2026, with 14 trials. The list ranks companies worldwide by the number of new interventional trials they lead in this area.
Top 10 at a glance
The full list
| Rank | Company | Headquarters | new industry-sponsored clinical trials (trials) |
|---|---|---|---|
| 1 | argenx | Netherlands | 14 |
| 2 | Novartis | Switzerland | 9 |
| 3 | UCB | Belgium | 8 |
| 4 | AstraZeneca | United Kingdom | 7 |
| 4 | Sarepta Therapeutics | United States | 7 |
| 6 | Apurano Pharmaceuticals | Germany | 6 |
| 6 | Avidity Biosciences | United States | 6 |
| 6 | Biogen | United States | 6 |
| 6 | China Immunotech | China | 6 |
| 6 | Neuralink | United States | 6 |
| 11 | Roche | Switzerland | 5 |
| 11 | Nanjing Bioheng Biotech | China | 5 |
| 13 | Eli Lilly | United States | 4 |
| 13 | Sanofi | France | 4 |
| 13 | Sinovac | China | 4 |
| 13 | MarsiBionics | Spain | 4 |
| 13 | PepGen | United States | 4 |
| 18 | Amgen | United States | 3 |
| 18 | Bristol Myers Squibb | United States | 3 |
| 18 | Chia Tai Tianqing (Sino Biopharm) | China | 3 |
| 18 | Vertex Pharmaceuticals | United States | 3 |
| 18 | Cartesian Therapeutics | United States | 3 |
| 18 | Chongqing Precision Biotech | China | 3 |
| 18 | Dianthus Therapeutics | United States | 3 |
| 18 | Entrada Therapeutics | United States | 3 |
| 18 | Immunovant | United States | 3 |
| 18 | Satellos Bioscience | Canada | 3 |
| 18 | Synchron | United States | 3 |
How this list is built
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list a condition that falls under neuromuscular diseases in the standard medical subject headings; withdrawn trials are not counted. Cancer trials are counted in the cancer lists instead. Subsidiaries and name variants are merged into the parent company ("Alexion Pharmaceuticals, Inc." and "AstraZeneca" are counted as AstraZeneca), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Every position is set by the data alone, by the same rules for every company. Spotted something to update? Write to info@stratummarketresearch.com with the list and the line, and we correct it within two working days.
For ranked companies: a free badge
Ranked companies can show this badge on their website, in a press release or on LinkedIn at no cost. Pick your company, then copy the code.
Frequently asked questions
Who is number one in the neuromuscular disease clinical trial sponsors ranking?
argenx ranks first with 14 trials (November 2023 to October 2026).
How is this ranking calculated?
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list a condition that falls under neuromuscular diseases in the standard medical subject headings; withdrawn trials are not counted. Cancer trials are counted in the cancer lists instead. Subsidiaries and name variants are merged into the parent company ("Alexion Pharmaceuticals, Inc." and "AstraZeneca" are counted as AstraZeneca), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Can a company pay to rank higher?
Positions come only from the counts described above, and inclusion is free. Every company is ranked by the same rules.
How often is the ranking updated?
Every list is recomputed each quarter from the latest public records, and the update date is printed on the page.
Can a ranked company use the badge?
Yes. Every ranked company can use the free web badge on this page on its website, in press releases and on social media.
Custom research
Looking for a specific market?
Tell us the market, the region and the decision you are making. We reply within one working day with a scope and a date.